It is currently 05 Aug 2020 05:44

All times are UTC + 5:30 hours [ DST ]




Post new topic Reply to topic  [ 1 post ] 
Author Message
 Post subject: PANCREATIC CANCER
PostPosted: 19 Jul 2020 23:56 
Offline
User avatar

Joined: 24 Mar 2013 02:28
Posts: 737
Pancreatic cancer is a highly fatal disease with a 5-year survival rate of approximately 10% in the USA, and it is becoming an increasingly common cause of cancer mortality.

Risk factors for developing pancreatic cancer include family history, obesity, type 2 diabetes, and tobacco use.

Patients typically present with advanced disease due to lack of or vague symptoms when the cancer is still localised.

High quality computed tomography with intravenous contrast using a dual phase pancreatic protocol is typically the best method to detect a pancreatic tumour and to determine surgical resectability.
Endoscopic ultrasound is an increasingly used complementary staging modality which also allows for diagnostic confirmation when combined with fine needle aspiration.

Patients with pancreatic cancer are often divided into one of four categories based on extent of disease: resectable, borderline resectable, locally advanced, and metastatic; patient condition is also an important consideration.

Surgical resection represents the only chance for cure, and advancements in adjuvant chemotherapy have improved long-term outcomes in these patients.

Systemic chemotherapy combinations including FOLFIRINOX (5-fluorouracil, folinic acid [leucovorin], irinotecan, and oxaliplatin) and gemcitabine plus nab-paclitaxel remain the mainstay of treatment for patients with advanced disease.

Data on the benefit of PARP inhibition as maintenance therapy in patients with germline BRCA1 or BRACA2 mutations might prove to be a harbinger of advancement in targeted therapy. Additional research efforts are focusing on modulating the pancreatic tumour microenvironment to enhance the efficacy of the immunotherapeutic strategies.

PARP INHIBITORS-PARP inhibitors, such as olaparib, attack tumors that are defective at DNA repair, especially in ovarian and breast cancers in women with inherited BRCA mutations. ... By drawing the immune cells to the tumor, PARP inhibitors could enable the immunotherapy drug to target their attack and enhance the therapeutic effect.

LANCET ONCOLOGY 27TH JUNE 2020


Top
 Profile Send private message  
 
Display posts from previous:  Sort by  
Post new topic Reply to topic  [ 1 post ] 

All times are UTC + 5:30 hours [ DST ]


Who is online

Users browsing this forum: No registered users and 2 guests


You cannot post new topics in this forum
You cannot reply to topics in this forum
You cannot edit your posts in this forum
You cannot delete your posts in this forum
You cannot post attachments in this forum

Jump to:  
cron